166 related articles for article (PubMed ID: 11986767)
1. A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer.
Gibbs DD; Pyle L; Allen M; Vaughan M; Webb A; Johnston SR; Gore ME
Br J Cancer; 2002 May; 86(9):1379-84. PubMed ID: 11986767
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
3. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
[TBL] [Abstract][Full Text] [Related]
4. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
6. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
[TBL] [Abstract][Full Text] [Related]
8. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.
Morgan MA; Darcy KM; Rose PG; DeGeest K; Bookman MA; Aikins JK; Sill MW; Mannel RS; Allievi C; Egorin MJ;
Gynecol Oncol; 2008 Sep; 110(3):329-35. PubMed ID: 18597837
[TBL] [Abstract][Full Text] [Related]
10. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
[TBL] [Abstract][Full Text] [Related]
11. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
12. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; DiSilvestro PA; Waggoner SE; Yamada SD; Armstrong DK; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Dec; 127(3):506-10. PubMed ID: 22943879
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors.
Campos SM; Matulonis UA; Penson RT; Lee H; Berkowitz RS; Duska LR; Fuller AF; Wilson KS; Puchalski TA; Supko JG; Seiden MV
Gynecol Oncol; 2003 Sep; 90(3):610-8. PubMed ID: 13678734
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
Tiersten AD; Sill MW; Knight D; Muggia F; Garcia AA; Swensen R; Warshal DP; Mannel RS; Fracasso PM
Gynecol Oncol; 2010 Sep; 118(3):303-7. PubMed ID: 20547415
[TBL] [Abstract][Full Text] [Related]
15. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
Pignata S; Scambia G; Savarese A; Breda E; Scollo P; De Vivo R; Rossi E; Gebbia V; Natale D; Del Gaizo F; Naglieri E; Ferro A; Musso P; D'Arco AM; Sorio R; Pisano C; Di Maio M; Signoriello G; Annunziata A; Perrone F;
BMC Cancer; 2006 Aug; 6():202. PubMed ID: 16882344
[TBL] [Abstract][Full Text] [Related]
16. Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube.
Fujiwara K; Suzuki S; Ishikawa H; Oda T; Aotani E; Kohno I
Int J Gynecol Cancer; 2005; 15(3):426-31. PubMed ID: 15882165
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
Konner J; Schilder RJ; DeRosa FA; Gerst SR; Tew WP; Sabbatini PJ; Hensley ML; Spriggs DR; Aghajanian CA
Gynecol Oncol; 2008 Aug; 110(2):140-5. PubMed ID: 18554700
[TBL] [Abstract][Full Text] [Related]
18. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
Morgan MA; Sill MW; Fujiwara K; Greer B; Rubin SC; Degeest K; Yamada SD; Waggoner S; Coleman RL; Walker JL; Mannel RS
Gynecol Oncol; 2011 May; 121(2):264-8. PubMed ID: 21277623
[TBL] [Abstract][Full Text] [Related]
19. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
Matulonis UA; Krag KJ; Krasner CN; Atkinson T; Horowitz NS; Lee H; Penson RT
Gynecol Oncol; 2009 Feb; 112(2):394-9. PubMed ID: 19058838
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
